Cathy Eng Archive — Page 1 of 2

Portrait of a smiling woman wearing a white lab coat, with dark hair pulled over one shoulder.
June 15, 2023

New treatment option for metastatic colorectal cancer prolongs survival

Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.

Portrait of a smiling woman wearing a white lab coat, with dark hair pulled over one shoulder.
March 16, 2023

Eng stresses need for clinical trial support at cancer forum

Vanderbilt’s Cathy Eng, MD, stressed the need for more patient participation and better funding for clinical trials to improve colorectal cancer treatment and outcomes during the White House Cancer Moonshot Colorectal Cancer Forum.

Portrait of Cathy Eng, MD, wearing a white medical coat over a pink patterned blouse.
March 2, 2023

Eng invited to White House Cancer Moonshot forum

Vanderbilt’s Cathy Eng, MD, has been invited to participate in the White House Cancer Moonshot Colorectal Cancer Forum.

VUMC NEWS logo in white lettering inside a cyan and yellow outlined square on a blue gradient background.
September 13, 2022

Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial

Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.

Exterior of Vanderbilt University Medical Center’s Vanderbilt-Ingram Cancer Center, Preston Research Building, with a curved glass façade, brick wings, and a covered entrance labeled “FRANCES WILLIAMS PRESTON BUILDING.”
August 18, 2022

Abramson, Eng, Johnson named to new VICC roles

Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.

VUMC NEWS logo in white lettering inside a cyan and yellow outlined square on a blue gradient background.
August 17, 2022

Trial for colorectal cancer drug reaches primary endpoint

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.